RU94020944A - Agent for intranasal influenza prophylaxis
- Google Patents
Agent for intranasal influenza prophylaxis
Info
Publication number
RU94020944A
RU94020944ARU94020944/14ARU94020944ARU94020944ARU 94020944 ARU94020944 ARU 94020944ARU 94020944/14 ARU94020944/14 ARU 94020944/14ARU 94020944 ARU94020944 ARU 94020944ARU 94020944 ARU94020944 ARU 94020944A
Уфимский научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уфимский научно-исследовательский институт вакцин и сывороток им.И.И.МечниковаfiledCriticalУфимский научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова
Priority to RU94020944ApriorityCriticalpatent/RU2086232C1/en
Publication of RU94020944ApublicationCriticalpatent/RU94020944A/en
Application grantedgrantedCritical
Publication of RU2086232C1publicationCriticalpatent/RU2086232C1/en
FIELD: medicine. SUBSTANCE: agent has the following composition, weight %: inactivated influenza vaccine 5-7; anhydrous lanolin 10-12, and Vaseline oil up to 100. Ointment form of influenza vaccine shows high immunogenicity as compared with other medicinal forms of influenza vaccine. EFFECT: high effectiveness, safety, reliable protection.
Claims (1)
Изобретение относится к медицине, а именно к средствам для специфической профилактики гриппа. Сущность изобретения заключается в приготовлении средства состава, вес.%: инактивированная грипозная вакцина 5 - 7, ланолин безводный 10 - 12 и вазелиновое масло до 100. Мазевая форма гриппозной вакцины обладает высокой иммуногенностью и имеет преимущества перед другими лекарственными формами гриппозной вакцины в удобстве, безопасности использования и надежной защите от гриппозной инфекции.The invention relates to medicine, namely to means for specific prophylaxis of influenza. The essence of the invention lies in the preparation of a composition, wt.%: Inactivated influenza vaccine 5-7, anhydrous lanolin 10-12 and liquid paraffin up to 100. The ointment form of the influenza vaccine has high immunogenicity and has advantages over other dosage forms of the influenza vaccine in convenience, safety use and reliable protection against influenza infection.
RU94020944A1994-06-031994-06-03Agent for influenza intranasal prophylaxis
RU2086232C1
(en)
LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR
Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
(S) -adenosyl-L-methionine (SAMe) and its physiologically compatible salts for the treatment of reperfusion injury induced by transient lesion ischemia (Use of (S) -Adenosy-L-Methionine Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
Compound, process for the preparation of a compound, medication, therapeutic or prophylactic agent for fungal infectious diseases, strain, use of a compound, method for the treatment or prevention of a fungal infection, and pharmaceutical composition